Allergan CEO Takes on Another Role as Chairman
As Paul Bisaro steps down as Allergan’s Executive Chairman of the Board of Directors after two years of service, he handed the reins to Brenton L. Saunders, who will also continue in his role as CEO and President. Bisaro, however, will remain a member of the board. Of Bisaro’s service, Saunders states, “During his tenure with our company, Paul has provided impressive leadership to Allergan and its Board of Directors. His strategic vision led the way to our transformation. Paul’s wisdom, partnership, and deep understanding of the biopharmaceutical industry have been invaluable to me as we transformed Allergan into a Growth Pharma leader, and I am happy that our Board will continue to benefit from his expertise.” Saunders will also continue in his roles as a member of the Board of Trustees at the University of Pittsburgh, The Business Council, and PhRMA.
New Partner at Finn Partners
Michael Heinley has been named partner and deputy of Finn Partners’ New York Health Practice. In his new role, he will collaborate with Gil Bashe, Managing Partner and Global Health Practice head, on the development of global affairs within the agency’s 14 offices.
“Michael has expansive industry knowledge across companies, functions, and audiences. His work with reputation, product, and technology offer our talent a competitive advantage in the marketplace as we prepare them to be our industry’s future leaders,” Bashe states. Heinley previously served at Johnson & Johnson as Vice President, Corporate Communications, and at Merck, where he cultivated global product communication skills.
Adare Pharmaceuticals
Peter Richardson, MD, joined Adare as Vice President, Research & Development and Chief Medical Officer. Dr. Richardson’s 30 years of experience in medical practice, research, and development will help accelerate the company’s development plans and implement its growth strategy. Prior to Adare, he served as Chief Medical Officer at Alcon, the eye care division of Novartis Corporation.
Amgen
Welcomes Lori Johnston back as Senior Vice President, Human Resources. Most recently she lead the human resources functions at Celanese Corporation, and before that she spent more than 10 years at Amgen in progressive leadership positions. She will report directly to Robert A. Bradway, Chairman and CEO.
Amorsa Therapeutics
Names board-certified anesthesiologist, pain specialist, and pharmacist, Anita Gupta, DO, PharmD to its Board of Directors. The respected pain medicine authority is often invited to news outlets such as CNN, Forbes, NBC, etc., to deliberate on breaking medical news.
Casebia Therapeutics
Names James W. Burns, PhD, as President and CEO. The industry veteran has nearly 30 years of R&D experience in the biopharmaceutical area, much of which he served at Sanofi-Genzyme.
Continuum Health Alliance
Strengthens its leadership team by naming Peter Bailey as President and Chief Operating Officer, with goals of further developing and expanding the company. Most recently, Bailey served as CEO of LabVantage Solutions. Bailey obtained his MBA at Wharton School of the University of Pennsylvania.
Decibel Therapeutics
Names company Co-founder Gabriel Corfas, PhD, to its Scientific Advisory Board. Corfas also is Director of Kresge Hearing Research Institute at the University of Michigan Health System and is a professor of Otolaryngology-Head and Neck Surgery and Associate Chair of Research in the Otolaryngology-Head and Neck Surgery department.
Finn Partners
The global marketing communications firm welcomes Arielle Bernstein Pinsof, MPP, as Partner to its Health Practice based in Chicago. The University of Chicago graduate most recently functioned as Group Vice President, Health Practice at Makovsky + Company.
Greater Than One Group
Promotes James Mackie to Partner. Mackie is an accomplished agency executive who brings extensive healthcare, advertising, and strategy experience with Fortune 500 companies to GTO.
Neon Therapeutics
An immuno-oncology company, appoints Richard Gaynor, MD, as President of Research and Development, taking over for Robert Tepper, MD. Dr. Gaynor worked at Eli Lilly’s oncology division for 15 years in senior roles, from which he recently retired. The industry veteran has produced roughly 150 publications and is part of multiple committees including AACR.
Ogilvy CommonHealth Worldwide
Announces the appointment of Nadine Oweis as Executive Vice President, Global Client Lead. The industry veteran has more than 10 years experience in healthcare communication, five of which have been with OCHWW in the medical education division of Ogilvy’s London extension.
Semma Therapeutics
Mark Fishman, MD, joins the biopharmaceutical company engaged in development of cellular therapies for diabetes treatment, as Chairman of the Board of Directors. Dr. Fishman is presently a professor at the Harvard Department of Stem Cell and Regenerative Biology and Chief of the Pathways Service in Medicine at the MGH.
Sentry Data Systems
The 340B compliance and advanced healthcare analytics solutions company welcomes John P. Ceraolo as its Chief Information Security Officer (CISO). He most recently served as CSO for 3Cinteractive. He will be responsible for the day-to-day executions of the company’s information security processes to ensure ongoing adoption of security best practices.
Sheppard Pratt Health System
The Baltimore-based company appointed Ray Dziesinski as VP and Chief Financial Officer. He brings 35 years of financial experience to the team. Dziesinski served as CFO of Clinical Services at Vanderbilt University Medical Center and CFO and Chief Treasury Officer of the Children’s Medical Center of Dallas. He has also contributed to multiple boards including the Georgia Nurses Association/Foundation. He replaces Gerald Noll, who will become the health system’s Treasurer.
